ZS:NASDAQZscaler, Inc. Analysis
Data as of 2026-06-17 - not real-time
$124.38
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Zscaler (ZS) is trading well below its 20‑day and 50‑day moving averages, with the price near the identified support level and a neutral trend despite a bearish MACD and an RSI hovering around the mid‑40s, indicating limited short‑term momentum. Volatility is extremely high at over 130% for the past 30 days, and volume has been tapering, which adds to the near‑term uncertainty. Fundamentally, the company delivered 25% year‑over‑year revenue growth and maintains a strong gross margin above 75%, but operating and profit margins remain negative, and cash flow is still the primary source of earnings. The balance sheet shows ample cash exceeding $3 billion against debt of roughly $1.9 billion, yielding a high debt‑to‑equity ratio, while the DCF model values the stock near $260, implying more than 50% upside from the current price. Recent material events include a 30% price plunge after the Q3 results, removal from the Nasdaq‑100 index, senior sales departures, and multiple investigations, all of which have pressured the share price but also created a potential entry point. Looking ahead, the rollout of AI‑focused Zero Trust products and a forward PE of 27—well below the industry average of 37—support a longer‑term bullish case, especially as analysts collectively rate the stock as a “Buy.”
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Significant price discount to DCF fair value
- Strong cash position offsetting debt concerns
- Recent share‑price weakness creating upside potential
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Sustained 25% revenue growth and expanding AI/Zero‑Trust product suite
- Forward earnings estimate turning positive with margin improvement expectations
- Analyst consensus of buy and target prices near $190
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Secular demand for cloud‑native security and Zero Trust architecture
- Undervaluation relative to intrinsic fair value and industry multiples
- Robust balance sheet enabling continued investment in innovation
Key Metrics & Analysis
Financial Health
Revenue Growth25.40%
Profit Margin-2.44%
P/E Ratio27.1
ROE-3.71%
ROA-1.36%
Debt/Equity78.94
P/B Ratio8.5
Op. Cash Flow$1.1B
Free Cash Flow$1.1B
Industry P/E37.0
Technical Analysis
TrendNeutral
RSI40.1
Support$119.50
Resistance$191.25
MA 20$141.32
MA 50$141.00
MA 200$212.33
MACDBearish
VolumeDecreasing
Fear & Greed Index88.5
Valuation
Fair Value$259.58
Target Price$193.05
Upside/Downside55.21%
GradeUndervalued
TypeBlend
Risk Assessment
Beta1.00
Volatility132.22%
Sector RiskHigh
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.